{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-107312","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.269425+00:00","generated_at":"2026-05-15T11:54:01.785908+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Relay Therapeutics reports zovegalisib + fulvestrant Phase 1/2 data: 11.1 mo median PFS at RP3D","bullets":["Median PFS of 11.1 months (95% CI 7.3-13.0) in 57 evaluable PI3Kα-mutated HR+/HER2- mBC patients.","Confirmed ORR 43% overall (15/35) and 52% in second-line patients (11/21).","Safety consistent with prior 600mg fasted; only 4 of 60 patients discontinued due to TRAEs.","Pharmacokinetics of 400mg BID fed comparable to 600mg BID fasted; most patients above IC80.","FDA Breakthrough Therapy designation already granted; Phase 3 ReDiscover-2 trial ongoing since mid-2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-107312","json":"https://secwatch.observer/filing/0001193125-26-107312.json","markdown":"https://secwatch.observer/filing/0001193125-26-107312.md","text":"https://secwatch.observer/filing/0001193125-26-107312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526107312/0001193125-26-107312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526107312/rlay-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:54:01.785908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}